Intranasal Vaccination of Humans with Recombinant Cholera Toxin B Subunit Induces Systemic and Local Antibody Responses in the Upper Respiratory Tract and the Vagina

CHARLOTTA BERGQUIST, EVA-LIZ JOHANSSON, TERESA LAGERGÅRD, JAN HOLMGREN, AND ANNA RUDIN*

Department of Medical Microbiology and Immunology, Göteborg University, S-413 46 Göteborg, Sweden

Received 13 January 1997/Returned for modification 17 February 1997/Accepted 3 April 1997

Forty-five volunteers were vaccinated twice intranasally with 10, 100, or 1,000 µg of cholera toxin B subunit (CTB). Blood and nasal and vaginal secretions were collected before and 1 week after the second vaccination from all volunteers, and the specific and total immunoglobulin A (IgA) and IgG titers were determined by enzyme-linked immunosorbent assay. Samples were also taken 6 months (n = 16) and 1 year (n = 14) after the vaccination. The 10- and 100-µg doses were well tolerated by the volunteers, but the 1,000-µg dose induced increased secretions from the nose and repetitive sneezings for several hours. The CTB-specific serum IgA and IgG increased 21- and 7-fold, respectively, 1 week after vaccination with the medium dose and increased 61- and 37-fold, respectively, after the high dose. In nasal secretions the specific IgA and IgG increased 2- and 6-fold after the medium dose and 2- and 20-fold after the high dose, respectively. In vaginal secretions the specific IgA and IgG increased 3- and 5-fold after the medium dose and 56- and 74-fold after the high dose, respectively. The lowest dose did not induce any significant antibody titer increases in serum or in secretions. The specific IgA and IgG levels in secretions were still elevated after 6 months but were decreasing 1 year after the vaccination. These results show that intranasal vaccination of humans with CTB induces strong systemic and mucosal antibody responses and suggest that CTB may be used as a carrier for antigens that induce protective immunity against systemic as well as respiratory and genital infections.

Mucosal vaccination leads to local production of antibodies and immunologic memory, which are important in the defense against many pathogens that colonize the surfaces in the gastrointestinal, respiratory, and urogenital tracts (18). Local production of immunoglobulin A (IgA) antibodies in the intestine after administration of microbial antigens perorally has been studied extensively, and this has resulted in the development of several oral human vaccines (19). According to the concept of the common mucosal immune system, immunocytes induced in the gut-associated lymphoid tissues migrate not only to the entire intestine but also to mucosal tissues of other organs (29). However, a compartmentalization of the mucosal immune system has been suggested, since oral, nasal, and rectal routes of vaccination induced greater immune responses at sites proximal to the site of induction than at distal sites (20, 35).

There is currently no doubt about the function of the respiratory tract as a good inductive site for mucosal as well as systemic antibody responses in experimental animals, but this knowledge has been poorly exploited for humans. Although a few studies have shown positive results with influenza virus, no human vaccines are routinely given intranasally or by inhalation (6, 13). Attempts have also been made to induce local antibody production by intravaginal immunization in animals, but both mucosal and systemic responses have been rather modest and dependent on the stage of the reproductive cycle (10, 30, 33). Intravaginal immunization of human volunteers resulted in a local antibody response which was greater than that after peroral immunization (43). However, animal experiments have shown that intranasal immunization induces a specific antibody response in the genital tract, although the mechanisms behind the immunologic connection between such anatomically and functionally remote organs are unknown (10, 12, 20, 38).

Most protein and polysaccharide antigens are poor mucosal immunogens, partly owing to their lack of receptor-binding properties (1). Nontoxic exceptions are antigens such as cholera toxin B subunit (CTB), Escherichia coli heat-labile enterotoxin (LT) B subunit, and genetically detoxified pertussis toxin (10, 17, 36). CTB, which binds to the GM1 ganglioside, has been used as a mucosal antigen in several animal models and is also a constituent of an oral cholera vaccine for human use (17, 18). CTB has also been employed as a mucosal carrier for nonbinding protein or polysaccharide antigens. Such constructs have been given orally, intranasally, or intravaginally to different species of animals but not to humans (2, 3, 8, 30, 38).

The objective of the present study was to assess the safety and immunogenicity of CTB given intranasally to humans and to evaluate whether such local immunization may elicit IgA and IgG antibody production not only on the nasal mucosa but also in serum and in the female genital tract.

MATERIALS AND METHODS

Vaccine. The vaccine consisted of purified CTB provided by SBL Vaccine, Stockholm, Sweden, and is a constituent of a licensed oral vaccine against cholera. The CTB was produced and purified from a recombinant strain of Vibrio cholerae lacking the cholera toxin A subunit gene (39). The vaccine was diluted in phosphate-buffered saline (PBS) to the different concentrations used. The content of endotoxin was 10 ng/mg of CTB protein.

Subjects and vaccination. Forty-five healthy Swedish volunteers of both sexes (24 female and 21 male), aged 19 to 35 years, gave informed consent to participate in the study, which was approved by the Swedish Medical Products Agency and the local Human Research Ethical Committee of the Medical Faculty, Göteborg University, Göteborg, Sweden. None of the volunteers had been vac-
cinated against cholera or had traveled during the last 3 years to a country where enterotoxicogenic *E. coli* or cholera is prevalent.

The intranasal CTB vaccine was given to three groups of volunteers in three different doses, i.e., 10, 100, or 1,000 μg/dose. Nineteen subjects received the 1000-μg dose and oral mucosa before and 1 week after vaccination and were questioned about ongoing allergic reactions, frequent nasal bleedings, and presence of tonsillitis before and 1 week after vaccination and were questioned about ongoing allergic reactions, frequent nasal bleedings, and adenoidectomy. Susceptibility for possible side effects was performed during five consecutive days after each vaccination. A questionnaire inquiring about the occurrence of symptoms that might be related to vaccination (nasal pain or itching, sneezings, nasal congestion, increased nasal secretions, nasal bleeding, dizziness, temperature, rash, and other reactions) was completed each day by each of the volunteers.

Sampling of sera and secretions. Blood, nasal and vaginal secretion samples were taken immediately before the first vaccination and 1 week after the second vaccination. Samples were taken after 6 months (*n* = 16) and 1 year (*n* = 14) from volunteers in the medium- and high-dose groups. The nasal secretions were collected by a double tampon method. A 0.5 × 2 cm tampon (Scholl, Solna, Sweden) was inserted into one of the nostrils with a pair of tweezers and a nasal speculum and left in place for approximately 2 h. After removal, the tampon was placed in 1 ml of PBS and stored at −70°C. The tampons were thawed and the fluid was squeezed out by centrifugation (2,200 × *g*) in a pierced Eppendorf tube placed on top of another tube and was immediately analyzed. The vaginal secretions were sampled by using a Polyclik tampon (10 by 30 mm) (Polyfrottets Company, Rockland, Mass.) (14, 21), which was inserted deeply into the vagina by the female volunteer herself. After 2 h, the tampon was taken out by the volunteer with the aid of a thread attached to the Polyclik, placed in 1.0 ml of PBS, and stored at −70°C. The Polycliks were thawed and centrifuged for 10 min at 4,500 × *g* in a pierced Eppendorf tubes as described above, and the samples were treated with bromelain (Sigma Chemical Company, St. Louis, Mo.) to solubilize the mucus (43). Twenty-five micrograms of bromelain was added per ml of sample and incubated for 60 min at 37°C, followed by centrifugation for 10 min at 9,500 × *g*. The intranasal CTB vaccine was given to three groups of volunteers in three different doses, i.e., 10, 100, or 1,000 μg/dose. Two doses were given with a 2-week interval, but because of adverse reactions, prompted us to discontinue recruitment of additional volunteers to this dose group. In the 100-μg dose group, 7 of 20 volunteers reported adverse reactions that were of the same type as described above but very mild and of much shorter duration. None of the volunteers in the 10-μg dose group experienced any adverse reactions. The physical examination of the nasopharynx mucosa before and after vaccination showed that there were no visible effects of CTB irrespective of the dose given.

RESULTS

Adverse reactions. To evaluate the feasibility of vaccinating humans intranasally with future CTB conjugates, we carefully recorded all signs and symptoms of adverse reactions. All volunteers in the 1,000-μg dose group experienced profuse nasal secretion, itching, and violent sneezings after the second vaccination. Four of them had similar reactions also after the first dose, and one of these volunteers withdrew. None of these reactions lasted for more than 1 day, and there were no systemic reactions, but the high frequency of local side effects prompted us to discontinue recruitment of additional volunteers to this dose group. In the 100-μg dose group, 7 of 20 volunteers reported adverse reactions that were of the same type as described above but very mild and of much shorter duration. None of the volunteers in the 10-μg dose group experienced any adverse reactions. The physical examination of the nasopharynx mucosa before and after vaccination showed that there were no visible effects of CTB irrespective of the dose given.

Serum antibody responses. CTB-specific IgA and IgG antibody titers in sera of all volunteers were determined. The GMs of the titers in the different groups before the first vaccination and 1 week after the second vaccination are shown in Fig. 1. The 100- and 1,000-μg doses induced impressive increases in the titers of anti-CTB IgA (GM < 0.001 in both cases) and IgG (GM < 0.001 in both cases), but no significant titers increases were seen in the 10-μg dose group. The fold increases of the CTB-specific IgA in the 100- and 1,000-μg dose groups were 21.2 and 61.4, respectively, and those for the IgG were 7.4 and 37, respectively. In the high-dose group all volunteers responded (>2-fold) with both specific IgA and IgG, and in the medium-dose group 18 of 20 and 17 of 20, respectively, responded. In the low-dose group only 8 of 18 volunteers responded with IgA, and 6 of 18 responded with IgG. The level of the preimmun CTB titers did not seem to influence the response to CTB (data not shown). We found no specific IgM titer increases irrespective of dose (data not shown).

To test whether intranasal vaccination with CTB induces allergic reactions associated with IgE production, we measured total IgE and specific IgE anti-CTB antibodies in serum before vaccination and 1 week after vaccination in all individuals in the high-dose group and in five of the volunteers in the medium-dose group. However, there was no increase in total IgE in any of these individuals with or without adverse reactions, nor could we detect any specific CTB-IgE in any of these 10 volunteers (data not shown).

Nasal antibody responses. Nasal secretions were collected by using a tampon method, which was shown to give a sufficiently high yield of antibodies (GM [95% confidence interval] 175 [149 to 203] μg/ml for total IgA and 199 [167 to 236] μg/ml for total IgG) to also allow detection of low levels of specific
antibodies in sample eluates. The levels of total IgA and IgG did not differ before and after the vaccination with CTB (data not shown). The pre- and postvaccination titers, adjusted to the total IgA or IgG content, are shown in Fig. 2, and the fold increases and frequency of responders are shown in Table 1.

To emphasize that the IgA and IgG titer increases in nasal secretions were not due to variations in total Ig, we show both the adjusted titers (Fig. 2) and the unadjusted titers (Table 1). The anti-CTB IgA titers in the nasal secretions were augmented moderately by vaccination with the 100- and 1,000-µg
doses, but the increases were not statistically significant (Fig. 2). At least part of the specific IgA found in nasal secretions was SIgA, since SC was detected in all but one postvaccination sample in the GM1 ELISA (data not shown). In contrast to the IgA titers, the IgG titers increased significantly in both the 100- and 1,000-μg dose groups (*P* < 0.001 and 0.002, respectively). The frequency of IgG responders was also higher than the frequency of IgA responders (Table 1). No specific IgM titer increases were found irrespective of dose (data not shown).

**Vaginal antibody responses.** Vaginal secretions were collected by using a Polywick tampon. As the total levels of IgA and IgG in pre- and postvaccination samples varied in some of the individuals, the specific antibody titers were adjusted to the total amounts of IgA and IgG, respectively. The GM (95% confidence interval) of the total IgA from all diluted (approximately 1/6) vaginal sample eluates was 16 (10 to 25) μg per ml, and that of the total IgG was 149 (100 to 217) μg per ml. The pre- and postvaccination titers are shown in Fig. 3, and the fold increases and frequency of responders are shown in Table 2. Similarly to the case for the nasal samples, the IgA and IgG titer increases in vaginal secretions were not due to variations in total Ig. To stress this, we show both the adjusted titers (Fig. 3) and the unadjusted titers (Table 2). The 10-μg dose did not induce any IgA or IgG increases, but the 100- and 1,000-μg doses induced considerable IgA and IgG increases in most individuals. Although both the IgA and IgG titers were augmented in the high-dose group, only the IgA increase was statistically significant (*P* < 0.013 and 0.06, respectively), because of the low numbers of individuals in the groups and the large difference in the magnitude of the adjusted titers between different individuals. All individuals in the 1,000-μg dose group responded with both IgA and IgG. Seven of nine individuals in the 100-μg dose group responded with either IgA or IgG. No significant IgM increases were found in any of the groups (data not shown). The presence of SC in the vaginal secretions thus indicated that at least part of the CTB-specific IgA is SIgA (data not shown).

**Antibody responses 6 months and 1 year after vaccination.** To determine the persistence of the antibody responses in serum and secretions, samples were taken from 16 volunteers 6 months after vaccination and from 14 of these volunteers 1 year after vaccination. The specific IgA titer in serum had declined significantly after 6 months (*P* < 0.001), but the specific IgG titer did not change significantly (Fig. 4). Both IgA and IgG levels were still elevated after 1 year compared with the pre-vaccination levels.

We found that both IgA and IgG CTB-specific titers (adjusted for the total content of IgA and IgG) in nasal secretions

**TABLE 1. Antibody responses against CTB in nasal secretions after intranasal vaccination**

<table>
<thead>
<tr>
<th>Ig and dose (μg)</th>
<th>GM of CTB-specific titerα on day:</th>
<th>Frequency of respondersβ</th>
<th>GM of fold increase for:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>21</td>
<td>All subjects</td>
</tr>
<tr>
<td>IgA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>198 (140–280)</td>
<td>155 (117–206)</td>
<td>3/18</td>
</tr>
<tr>
<td>100</td>
<td>156 (110–221)</td>
<td>261 (190–359)</td>
<td>8/20</td>
</tr>
<tr>
<td>1,000</td>
<td>746 (457–1,214)</td>
<td>1,263 (706–2,259)</td>
<td>3/5</td>
</tr>
<tr>
<td>IgG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>23 (18–30)</td>
<td>28 (22–35)</td>
<td>6/18</td>
</tr>
<tr>
<td>100</td>
<td>14 (11–17)</td>
<td>74 (50–110)</td>
<td>14/20</td>
</tr>
<tr>
<td>1,000</td>
<td>29 (21–39)</td>
<td>525 (234–1,173)</td>
<td>5/5</td>
</tr>
</tbody>
</table>

α The range (±1 SEM) is given in parentheses.
β Responders were defined as having a >2-fold titer increase.
γ The fold increases are calculated from the titers adjusted for total Ig content in the sample.

**FIG. 3.** CTB-specific IgA and IgG (units per microgram of total Ig) in vaginal secretions before (empty bars) and 1 week after (filled bars) the second vaccination with either, 10, 100, or 1,000 μg per dose. Error bars show SEMs.
had increased significantly 6 months after vaccination compared to titers obtained after 1 week (P < 0.005 and 0.01, respectively) (Fig. 5). The long-term persistence of the nasal antibody responses was unexpected, particularly as the serum IgA had decreased substantially. However, 1 year after vaccination, the CTB-specific IgA and IgG titers had declined compared with the titers obtained 6 months after vaccination.

However, the IgG titers were still elevated compared with the prevaccination levels.

In contrast to the CTB-specific IgA and IgG titers in the nasal secretions, which increased, and to the IgA titers in serum, which decreased, the IgA and IgG titers (adjusted for the total content of IgA and IgG) in vaginal secretions were maintained at the same level after 6 months as after 1 week (Fig. 6). After 1 year, the CTB-specific IgA and IgG titers had declined significantly compared with the values 1 week after the vaccination (P = 0.0011 and 0.03, respectively).

**DISCUSSION**

Recent animal experiments have indicated the possibility of using protein antigens as vaccines or vaccine carriers administered locally on the respiratory mucosa to induce immune responses at local and distant mucosae as well as systemically (10, 20, 38). This is the first study to show that the potential mucosal carrier CTB given intranasally may elicit IgA and IgG antibody production not only on the nasal mucosa and in serum but also in the human female genital tract. Moreover, the dose of CTB that can safely be given intranasally to humans with no or tolerable side effects was determined.

Our results show that intranasal vaccination of humans gives rise to impressive serum antibody responses of both specific IgA and IgG. As recombinant CTB (rCTB) is a component of the oral cholera vaccine, it is possible to compare the magnitudes of the fold increases in serum after intranasal vaccination.
with those after peroral vaccination (23). Giving the same dose by the nasal or oral route resulted in about three-times-higher fold increases of specific serum IgA or IgG after intranasal vaccination than after oral vaccination. Administration of a 10-times-lower dose intranasally resulted in magnitudes of serum IgA and IgG increases similar to those with the peroral vaccine. This indicates that the intranasal route may be more effective in inducing systemic responses than the oral route, which is supported by animal studies using other antigens coupled to CTB given by various routes (3, 16, 44).

We found that intranasal vaccination with both the medium and high doses of CTB induced substantial IgA and IgG titer increases in vaginal secretions already 1 week after vaccination. The persistence of the antibody response in vaginal secretions 6 months after vaccination is noteworthy, since mucosal responses are generally regarded as short-lived. Although local application of various antigens in the vagina has been shown to elicit a specific IgA antibody response in the vaginal secretions in both humans and animals (26, 43), intranasal immunization generally induced a higher vaginal response than intravaginal administration in animals (10, 12, 20). The advantages of immunizing intranasally may be not only a higher efficacy in eliciting a vaginal immune response but also a more effective induction of a systemic immune response and a more convenient route of administration. Moreover, it might be difficult to use intravaginal immunization in humans if the time point for vaccination has to be synchronized to the menstrual phase, as suggested by results showing that induction of immune responses in the mouse vagina correlates with the stage in the estrous cycle (20, 33). Intranasal vaccination is also applicable to both sexes and might induce an immune response in the male urogenital tract, which has not yet been evaluated.

A few studies with animals suggest that oral vaccination may also induce local immunity in the genital tract (7, 14, 20, 30). However, several of these studies indicate that peroral vaccination is not as efficient as intranasal vaccination in inducing a specific response in the vaginal secretions (20, 30). Notably, a study comparing oral and intravaginal vaccination with a whole-cell cholera vaccine containing rCTB in humans showed that oral vaccination does not induce significant responses against CTB in the vaginal secretions, despite the appearance of a strong serum response in some of the volunteers (43). Moreover, since experiments with animals have indicated that specific IgA and IgG antibody-producing cells appear in the vaginal tissues after intranasal immunization (25, 37), it is very likely that the majority of the IgA antibodies are locally produced and not transudated from serum. The origin of the specific IgG in vaginal secretions is probably both cells in the vaginal tissue and serum, since specific IgG antibodies against tetanus toxoid have been found in human vaginal secretions after parenteral vaccination (4).

In the common mucosal immune system, lymphocyte precursors are induced in inductive mucosal lymphoid tissues, enter the circulation, and end up in various mucosal and systemic effector sites (29, 31). The mechanism for the appearance of lymphocytes in the genital tract after immunization in the airways is not clear, but it may be a result of the existence of common adressesins for lymphocyte homing receptors in the
two disparate tissues. However, the lymphocyte receptors or endothelial adhesion molecules responsible for lymphocyte homing to the respiratory and the genital tracts have not yet been characterized.

It has been established in studies with both animals and humans that intranasal immunization elicits an antibody response in the upper respiratory tract (3, 11, 13, 15, 35). Our results showing that the CTB-specific IgG response dominated over the IgA response in the nose indicate that the induction of antibody isotypes to CTB in the upper respiratory tract is different from the response in the intestinal tract (34). In keeping with our results, a previous study showed that the predominant total Ig-secreting cell population in the tonsils and adenoids secreted IgG and not IgA (35), and intranasal vaccination of humans with influenza virus induces a higher proportion of IgG-secreting cells than IgA-secreting cells in blood (32). Moreover, immunohistochemical examinations of the nasal mucosa have shown that substantial numbers of IgG-producing cells are present in the stroma beneath the surface epithelium (5). Since enzymatic degradation of IgG in the respiratory tract is probably a minor problem compared with that in the gastrointestinal tract, the produced IgG may be an important contributor to protection (28). We were surprised by the relatively modest increases of specific IgA titers in the nasalsecretions 1 week after the vaccination. However, the maximal response might occur later than 1 week after the vaccination, since the specific IgA titers had increased further after 6 months. It has been reported that intranasal vaccination of humans with live influenza virus induced a specific IgA response that was delayed compared with that after oral vaccination (32). We are currently investigating the kinetics of the anti-CTB antibody responses after intranasal and peroral vaccination.

Although the rCTB preparation that we have used is completely free of CT and contains low levels of endotoxin, the administration of 1,000 μg per dose induced irritating local adverse reactions in all of the volunteers. In spite of the relatively short duration of the local reactions and the absence of systemic reactions, their existence would appear to preclude the practical use of this dose intranasally in a vaccine formulation. About one-third of the volunteers also experienced local adverse reactions with 100 μg of rCTB per dose, but these reactions were very mild and were considered tolerable by the affected individuals. In a recent study, 100 μg of the B subunit of LT of enterotoxigenic *E. coli* with trace amounts of LT was given intranasally to humans and resulted in a high frequency of both local and general reactions, which indicates that the LT component is very reactogenic (15). Thus, the necessity of using completely detoxified proteins in humans is obvious. As the adverse effects were very mild after the 100-μg dose of rCTB, a higher dose would probably be tolerated and would perhaps increase the immune response even further. A CTB dose of 330 μg has in fact been given to humans in a recent study, without any reported adverse effects (9). Because of the reported effect of CT or CTB with trace amounts of CT to induce IgE antibodies against some protein antigens when administered perorally or intranasally to mice (40, 42), we were interested in whether rCTB would induce an increase in total or CTB-specific IgE after intranasal administration to humans. However, this was not the case, since we found no elevations in either the total or CTB-specific IgE antibody content in serum. Similar results were also found after peroral vaccination with...
the whole-cell rCTB cholera vaccine (24). Thus, the systemic and severe local side effects as well as stimulation of IgE production in the studies mentioned above seem to be caused by the holotoxins.

The present study is the first to show that intranasal vaccination elicits specific IgA and IgG antibodies in the vaginal secretions of humans. The effective induction and long-term persistence of systemic antibodies as well as local antibodies in the upper respiratory tract and vagina suggest that rCTB may be used as a vaccine carrier for antigens from pathogens with either the respiratory, genital, or systemic site of entry. In future studies we will evaluate whether intranasal vaccination may elicit a specific antibody response also in bronchoalveolar lavage fluids and in the male urogenital tract.

ACKNOWLEDGMENTS

This work was supported by the Swedish Medical Research Council (grant 16X-3383); the Commission of the European Communities for Biomolecular Research (BIOMEREX 136); and the U.S. National Institutes of Health (grant AI1-35543; the Faculty of Medicine, Göteborg University; Konrad och Helfrid Johansson fond; Wilhelm och Martina Lundgrens stiftelse; and the Göteborg Medical Society. We gratefully acknowledge all volunteers, SBL Vaccine for providing us with the CTB vaccine preparation, and Astra Draco for their gift of the nasal spray devices. We are also indebted to Maria Hjulström for skillful technical assistance and to Lars Åke Nilsson for advice on IgG analyses.

REFERENCES


Editor: J. R. McGhee